Alzheimers disease (AD) is one of the most common neurodegenerative diseases, accounting for 60% to 70% of all types of dementia. It is mainly characterized by progressive memory loss, cognitive decline and behavioral abnormalities.
Conditions
Interventions
Group AD:NA
Sponsors
PEKING UNIVERSITY SHENZHEN HOSPITAL
Eligibility
Sex/Gender
All
Age
55 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1.AD group: aged between 55 and 85 years old; meeting the clinical diagnostic criteria for AD as per NIA-AA 2018, initially diagnosed as Alzheimer's disease by a professional physician and without previous AD treatment; able to provide peripheral blood samples and having given informed consent; agreeing to undergo clinical evaluations and data collection related to the study; among them, 200 patients who need lumbar puncture for clinical purposes will have their cerebrospinal fluid (CSF) samples collected simultaneously. 2.Healthy group: Ages ranging from 55 to 85 years old, matched for age with the AD group (±5 years), and population-matched in terms of major demographic characteristics such as gender and ethnicity; without a history of neurodegenerative diseases, mental disorders, or cognitive impairments; able to provide peripheral blood samples, and having given informed consent; with normal cognitive function in clinical assessment (e.g., MMSE score within the normal range); without severe physical or systemic diseases that affect judgment, except for those excluded.
Exclusion criteria
Exclusion criteria: 1.Group AD: Currently in the period of pregnancy or lactation; Had other neurodegenerative diseases or malignant tumors before enrollment, or had a clear diagnosis of AD previously; Received blood transfusion, immunoglobulin or blood product treatment within the past 30 days; Genetically tested and found to carry pathogenic genetic mutations related to AD (such as PSEN1, APP, etc.); The investigator, after comprehensive assessment, determined that they are not suitable to continue participating in this study. 2.Healthy group: Currently in the period of pregnancy or lactation; Had previously suffered from other neurodegenerative diseases or malignant tumors before enrollment, or had a clear diagnosis of AD; Received blood transfusion, immunoglobulin or blood product treatment within the past 30 days; Through genetic testing, it was confirmed that they carry pathogenic genetic mutations related to AD (such as PSEN1, APP, etc.); After comprehensive assessment by the researchers, it was determined that they are not suitable to continue participating in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Multimodal integration model; | — |
Countries
China
Contacts
Public ContactJun Hu
PEKING UNIVERSITY SHENZHEN HOSPITAL
Outcome results
None listed